Indian Association Calls for Biotechnology Fund
The Associated Chambers of Commerce and Industry of India (Assocham, www.assocham.org) have called for the establishment of a National Biotechnology Development Fund and a National Nanotechnology Development Fund, with outlays of approximately US $1 billion (Rs. 4,800 crore) and US $2 billion (Rs. 9,600 crore) respectively.
The Associated Chambers of Commerce and Industry of India (Assocham, www.assocham.org) have called for the establishment of a National Biotechnology Development Fund and a National Nanotechnology Development Fund, with outlays of approximately US $1 billion (Rs. 4,800 crore) and US $2 billion (Rs. 9,600 crore) respectively.
The funds, controlled by an autonomous management structure, would develop infrastructure-intensive industries in both the nanotech and biotech areas. Assocham contends that the establishment of national biotechnology and nanotechnology funds will inspire further development and motivate industry leaders to create adequate space within the Indian economy to allow for further expansion in these areas.
In the group’s recommendations submitted to the Indian government, the association also asked that a non-lapsable knowledge-acquisition fund be created to encourage students to return to studying the sciences. The association also contends that the government should create National Institutions of Nanotechnolgy–Biotechnology (IINBTs), with a structure similar to that of India’s Institutes of Information Technology.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
